HIF1α or HIF2α: Enhancing CD8+ T-cell Fitness for Antitumor Immunity.

Adoptive T-cell therapy requires the transferred lymphocytes to adapt to the hypoxic tumor microenvironment. In this issue, Veliça and colleagues found that modified HIF2α expression in CD8+ T cells increases antitumor efficacy.See article by Veliça et al., p. 401.